相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer
Hui Yu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
Stephen Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab
Edoardo Lenci et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Prognostic role of pretreatment lung immune prognostic index in extensive-stage small-cell lung cancer treated with platinum plus etoposide chemotherapy
Weixiang Qi et al.
CANCER BIOMARKERS (2021)
Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab
Wei-Xiang Qi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
Alessio Cortellini et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer
G. L. Banna et al.
ESMO OPEN (2021)
Prognostic Role of Lung Immune Scores for Prediction of Survival in Limited-stage Small Cell Lung Cancer
Leon Schnoeller et al.
IN VIVO (2021)
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
Charles M. Rudin et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The clinicopathological and prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in small cell lung cancer: A meta-analysis
Yan Lu et al.
PLOS ONE (2020)
Lung immune prognostic index as a prognostic factor in patients with small cell lung cancer
Kei Sonehara et al.
THORACIC CANCER (2020)
Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs)
Ye Li et al.
FRONTIERS IN ONCOLOGY (2020)
Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab
Giuseppe Luigi Banna et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-I Inhibitors
Shixue Chen et al.
JOURNAL OF HEPATOCELLULAR CARCINOMA (2020)
Pretreatment lactate dehydrogenase may predict outcome of advanced non small-cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis
Zhibo Zhang et al.
CANCER MEDICINE (2019)
Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer
Dickran Kazandjian et al.
JAMA ONCOLOGY (2019)
The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors
Daniel E. Meyers et al.
CANCERS (2019)
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
Matthew D. Hellmann et al.
CANCER CELL (2018)
Current and future therapeutic approaches for the treatment of small cell lung cancer
Antonio Rossi et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2018)
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer
Laura Mezquita et al.
JAMA ONCOLOGY (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Lactate Dehydrogenase (LDH) as a Surrogate Biomarker to Checkpoint-Inhibitors for Patient with Advanced Non-Small-Cell Lung Cancer (NSCLC)
Am Martinez De Castro et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
Stefan Diem et al.
LUNG CANCER (2017)
Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
Stephen J. Bagley et al.
LUNG CANCER (2017)
Predictive Factors for Poor Progression-free Survival in Patients with Non-small Cell Lung Cancer Treated with Nivolumab
Yoshihiko Taniguchi et al.
ANTICANCER RESEARCH (2017)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer
N. Shao et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2015)
A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours
Ashvin Paramanathan et al.
SURGICAL ONCOLOGY-OXFORD (2014)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Small cell lung cancer: Have we made any progress over the last 25 years?
Brian E. Lally et al.
ONCOLOGIST (2007)
Paradoxical roles of the immune system during cancer development
KE de Visser et al.
NATURE REVIEWS CANCER (2006)
International lung cancer trends by histologic type:: male:female differences diminishing and adenocarcinoma rates rising
SS Devesa et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization
RL Camp et al.
CLINICAL CANCER RESEARCH (2004)
分享论文
